Another compound showing an ability to inhibit the catalytic activity of GLS2 is 986, a member of the benzophenanthridinone family, which was originally identified as a GAC inhibitor with anticancer properties in human breast cancer cells MDA-MB231 and SKBR3, as well as in a B-cell lymphoma model in vitro and in vivo [27]. Here, GLS is linked to breast carcinoma.